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Abstract
Background: Venous gangrene complicating deep vein thrombosis in the context of anticoagulation use in
patients with gynecologic malignancy is rarely reported. We report an unusual presentation of venous gangrene of the
lower limbs associated with warfarin therapy in a 53-year-old woman from the Cook Islands with an occult
ovarian cancer.
Case presentation: A 53-year-old woman of Cook Islands origin presented with exertional dyspnea, rapid
atrial fibrillation, bilateral lower limb edema, and painful digital ischemia of her hallux. She was on warfarin
therapy for atrial fibrillation and had a stable therapeutic international normalized ratio. Bilateral proximal
lower limb deep vein thrombosis and digital gangrene subsequently developed in the setting of a supratherapeutic
international normalized ratio and platelet count depletion. Her warfarin was reversed and heparin therapy was
commenced with resulting correction of her thrombocytopenia.
Conclusions: We would like to attract the attention of the reader to the potential hazard of the use of warfarin in
patients with malignancy. In our case, we also demonstrated a predictive value of supratherapeutic international
normalized ratio and platelet count depletion that could herald massive thrombosis and gangrene in a patient
who was previously stable on warfarin therapy. Early recognition and prompt reversal of warfarin in these circumstances
is essential to correct the unbalanced prothrombotic process that leads to extensive thrombosis and gangrene. The
outlook of such cases remains dismal and results in extensive morbidity and mortality.
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Background
Venous gangrene complicating deep vein thrombosis
(DVT) in the context of anticoagulation use in pa-
tients with gynecological malignancy is rarely reported
[1]. The diagnosis can be delayed if not suspected
due to its rare occurrence and invariably result in a
fatal outcome [2]. This case report documents a 53-
year-old woman who developed bilateral lower limb
DVT while being on a therapeutic dose of warfarin
for atrial fibrillation (AF) which rapidly progressed to
venous gangrene of both feet and subsequently was
discovered to have ovarian cancer.
Case presentation
A 53-year-old morbidly obese woman with a body
mass index (BMI) of 70 of Cook Islands origin had a
background of obesity-induced hypoventilation and
metabolic syndrome, chronic kidney disease, and gout.
She also had ischemic cardiomyopathy and received
oral anticoagulation with warfarin for AF. She had a
stable international normalized ratio (INR) for 8 years
prior to her presentation. She complained of constitu-
tional symptoms, weight loss, fatigue, and mild ab-
dominal discomfort and distension in the 4 months
prior to her presentation. She was admitted due to
ongoing exertional dyspnea, bilateral painful lower
limb edema, and rapid AF.
On her second day in hospital, she developed worsen-
ing ischemia of her first, second and third toes of her
right foot and second and third toes of her left foot. Her
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toes became dusky and turned black in color and more
extensive discoloration was noted on the right side
(Fig. 1). Pulsations remained intact and arterial Doppler
ultrasound of her lower limbs failed to demonstrate sig-
nificant arterial disease. Distal vascular disease was
thought to be responsible for her toe gangrene. Her
warfarin was still continued at this point.
A computed tomography (CT) scan of her abdomen
(Fig. 2) and pelvis revealed an 18-cm cystic ovarian mass
and free abdominal ascites. An ultrasound-guided ascitic
tap was negative for malignant cells and her serum to asci-
tes albumin gradient was 12 g/L. Subsequently, her plasma
levels of cancer antigen-125 (CA-125) were 3410 u/ml
(normal <35), human epididymis protein 4 (HE4) was
30,300 pmol/L (normal <70) and Risk of Ovarian Malig-
nancy Algorithm (ROMA) was 100 %. Values of ROMA
>25.3 % in postmenopausal women indicate high risk of
malignancy with >95 % sensitivity and >76 % specificity [3].
On the third day, her INR progressively increased
to 4.5 and simultaneously her platelet count de-
creased from 154 to 108×109/L. At the same time,
serial activated partial thromboplastin time (aPTT)
measurements remained normal at 26 to 36 seconds
and the derived fibrinogen levels also remained nor-
mal on serial measurements 3.8 g/L (1.7 to 4.5 g/L).
No red cell fragments were seen on repeat blood film. The
result of a qualitative D-dimer test was weakly positive.
With the aforementioned results, coagulopathy
related to both warfarin and an underlying ovarian
cancer was suspected. Her anticoagulation with
warfarin was reversed with vitamin K as evidenced
by the drop in her INR (Fig. 3) and switched to an
unfractionated heparin administered intravenous
infusion. A subsequent venous Doppler confirmed
extensive bilateral lower limb DVT involving all deep
veins on her left and an acute thrombosis of the
popliteal vein on her right side.
We noted that her platelet count increased immedi-
ately after administration of vitamin K and intravenously
administered heparin and peaked to 246×109/L on the
following day (Fig. 4). Because of her severe renal im-
pairment, the use of either low molecular weight heparin
or direct oral anticoagulants was precluded. She was
continued on an intravenous infusion of heparin for the
subsequent 2 weeks.
Serology revealed positive hepatitis B surface anti-
gen, positive qualitative hepatitis B virus (HBV)-DNA,
positive core-HBV (total antibodies, negative immuno-
globulin M antibodies) and envelope-HBV antibodies
suggestive of chronic hepatitis B infection. Her serum
and plasma cryoglobulins, anti-beta 2 glycoprotein,
and anti-cardiolipin (immunoglobulin G) antibodies
were negative. Her protein C (PC) and factor VII
levels were not measured since she was on chronic
warfarin therapy. Her thrombin-antithrombin com-
plexes (TAT) were not measured.
An associated oliguric acute kidney injury was man-
aged conservatively and an ultrasound Doppler of her
renal vein and renal artery ruled out thrombosis. Her es-
timated glomerular filtration rate (eGFR) was stable at
around 20 mL/minute/1.73 m2.
Our patient was deemed to be at an extremely high
perioperative risk for a debulking laparotomy and was
deemed not suitable for surgery, thus a histological
specimen was not pursued. In addition, her Eastern
Cooperative Oncology Group (ECOG) functional state
score of 4 and comorbidities excluded her from
chemotherapy.
Eventually, due to her sepsis associated with venous
gangrene of both feet, coagulopathy, gynecological ma-
lignancy, cardiomyopathy, and end-stage renal failure,
palliative treatment was offered and she died 19 days
after admission.
Discussion
The development of ovarian cancer in our patient while
being on warfarin is suspected to be the inciting event to
our patient’s coagulopathic state and the development of
venous gangrene. The presence of highly positive HE4,
CA-125 and ROMA scores along with a large pelvic
mass makes the diagnosis of ovarian malignancy most
likely despite the negative ascitic cytology. It is likely that
our patient had chronic disseminated intravascular co-
agulation (DIC; compensated DIC) in lieu of the ovarian
cancer. This is a known precipitant of venous thrombo-
embolism (VTE) in patients with cancer [4]. However, it
is interesting that while being on a therapeutic dose of
warfarin, she developed extensive thromboembolic
complications.
Fig. 1 Photograph revealing the extent of digital ischemia with a
bandaged right hallux due to serous wound discharge
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We excluded antiphospholipid syndrome or associated
vasculitis and deemed that our patient was unlikely to
have a primary thrombotic state because she had no
family history or personal history of thrombotic
tendencies and was not on any attributable medications
except warfarin. As a limitation to our approach, a histo-
logical sample of the mass was not obtained. This would
have confirmed the subtype of ovarian cancer and added
to the strength of association in our case report.
Warfarin is a commonly used anticoagulant. The
anticoagulant properties of warfarin are attributed to
the suppression of vitamin K-dependent procoagulant
factors: prothrombin (factor II), factor X, factor IX
and factor VII. On the other hand, the prothrombotic and
coagulant properties of warfarin may result from the un-
balanced suppression of the vitamin K-dependent natural
anticoagulants: PC and protein S [5]. This may occur
upon initiation of warfarin therapy and is attributed to the
earlier depletion of the anticoagulant factors due to their
shorter half-life resulting in a prothrombotic state [3].
This exceptional situation of warfarin-induced unbal-
anced suppression of anticoagulant factors has also
been described in patients with cancer [5, 6]. In these
patients there is direct activation of their clotting sys-
tem by cancer cells, and indirectly by activation of
platelets, monocytes and endothelial cells. Cytokines
such as tumor necrosis factor-α and interleukin-1β re-
leased by tumor cells activate the tissue factor (TF) [2].
Despite depletion of factor VII in patients treated with
warfarin, patients with cancer may continue to have un-
controlled activation of coagulation which is reflected by
markedly increased levels of TAT complexes. This pro-
coagulant activity is also enhanced by failure of PC to
down-regulate thrombin generation [1].
It was found that a supratherapeutic INR (≥6.0),
warfarin-induced PC and protein S deficiency, obesity,
Fig. 3 International normalized ratio results. International normalized ratio results on y-axis; date of result on x-axis. Note warfarin was ceased and reversed on
5 June 2015. The red bars represent INR results above the normal reference range which is represented by the blue bars. INR international normalized ratio
Fig. 2 Non-contrast abdominal computed tomography of the patient
revealing the 18-cm large ovarian lesion with moderate volume periton-
eal ascites
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and metabolic syndrome were among several factors to
predispose to venous thrombosis and gangrene in pa-
tients with cancer [2].
A similar outcome of venous thrombosis and gangrene
that results from warfarin therapy has been described in
patients with antiphospholipid antibody syndrome and
in patients with heparin-induced thrombocytopenia
(HIT) [2, 5]. In patients with HIT, activation of the
thrombotic pathway occurs due to an antibody-mediated
process. Immunoglobulin G antibodies bind to the plate-
let factor 4 (PF4)-heparin complexes. The resulting im-
mune complexes crosslink receptors on platelets and
monocytes thus activating them. The activation of plate-
lets and monocytes increases thrombin generation with
subsequent thrombocytopenia due to consumptive coag-
ulopathy. Patients with established HIT may develop
venous limb gangrene if warfarin is commenced due to
the suppression of factor C and S that occurs upon initi-
ation of warfarin therapy [7]. In the case of antiphospho-
lipid antibody syndrome, initiation of warfarin therapy
can lead to thromboembolism and venous gangrene by
similarly suppressing the levels of PC and protein S on
top of a preexisting hypercoagulable state [5].
Warfarin-induced gangrene may present as the classic
picture of coumarin skin necrosis with involvement of
the dermal and sub-dermal tissues predominantly at
central (non-acral) sites such as the breast, abdomen,
thigh, calf, and forearm [1]. This is particularly described
in patients with heterozygous PC deficiency [2]. On the
other hand, venous limb gangrene complicating warfarin
therapy presents with digital (acral) necrosis in associ-
ation with DVT. Typically, the arterial circulation re-
mains patent with thrombosis involving both the larger
veins and the smaller venules and microcirculation [1].
Of interest, in our patient the extent of digital gangrene
due to occlusion of the microcirculation did not correl-
ate to the degree of thrombosis of the larger veins on
the same side.
Phlegmasia cerulea dolens, on the other hand, is a
rare form of massive proximal venous thrombosis of
the lower limbs which is often associated with arterial
insufficiency and absent arterial pulsations. It may pro-
gress to venous gangrene and compartment syndrome
and has been described in patients with particularly
thrombogenic cancers including gastric, esophageal, lung,
pancreatic, renal, and ovarian cancers, as well as acute
myelogenous leukemia and non-Hodgkin’s lymphoma [8].
In a recent article published by Warkentin et al. in
May 2015 [1], a novel and clinically distinct syndrome of
severe venous limb gangrene (phlegmasia/venous limb
gangrene) in ten patients with metastatic cancer was de-
scribed. This group of patients was under treatment for
DVT with heparin bridging and warfarin. They devel-
oped a rise in platelet count upon initiation of heparin
therapy, which was followed by a drop in the count
when heparin was discontinued. They also showed
supratherapeutic INR levels upon commencement of
warfarin therapy. The authors demonstrated an elevated
TAT to PC activity ratio reflecting an underlying dis-
turbed procoagulant–anticoagulant balance [1].
Our patient had previously maintained a stable thera-
peutic INR level with warfarin therapy. The occurrence
of venous gangrene was heralded by prolongation of
INR and progressive thrombocytopenia. Thrombo-
embolism developing in patients while on warfarin ther-
apy may either be due to a sub-therapeutic INR or due
to a new procoagulant state. In this context, pro-
longation of INR and thrombocytopenia indicates an
Fig. 4 Platelet count results. Platelet count results on y-axis; date of result on x-axis. Note warfarin was ceased and reversed on 5 June 2015
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ongoing consumptive coagulopathy. In our patient
this state was most likely perpetuated by the ovarian
cancer. Warfarin depletes PC levels and in patients
with cancer with enhanced thrombin generation, a
prothrombotic state is established with development
of microvascular thrombosis [2]. After administering
vitamin K and commencement of heparin therapy,
thrombocytopenia was corrected. This indicated inter-
ruption of underlying cancer-mediated thrombosis
and repletion of PC and protein S.
In patients maintained on warfarin therapy, an estima-
tion of PC and factor VII levels would be unhelpful in
the diagnosis of ongoing consumptive coagulopathy.
Warkentin et al. suggested using the ratio of TAT to PC
levels to demonstrate the procoagulant–anticoagulant
imbalance [1]. In our scenario, the dropping platelet
count coupled with a rising INR was taken as a surro-
gate marker for the hyperactive prothrombotic pathway.
Conclusions
This case demonstrates that the association of new onset
thrombocytopenia when coupled with INR prolongation
during warfarin therapy may herald massive thrombosis
and should alert the clinician to an underlying consump-
tive coagulopathy. If suspected, evidence for an activated
thrombotic process should be sought. In patients treated
with warfarin therapy an estimation of PC and factor VII
levels would be unhelpful but TAT levels may be more
useful. Warfarin therapy in this situation should be
reversed and a suitable alternative anticoagulant agent
should be considered.
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